Shots:
- Jupiter has partnered with Zina to support its P-IIa trial of Jotrol for assessing its safety & tolerability (1EP), and PK/PD (2EP) in Parkinson’s pts
- As per the agreement, Zina will provide services for P-IIa trial such as protocol design assistance (PK, biomarkers), regulatory strategy, & trial site selection
- Jotrol (micellar formulation) enhances resveratrol’s bioavailability while reducing GI side effects. Preclinical studies show its potential in targeting neurodegeneration biomarkers, supporting its potential for Parkinson’s & other CNS disorders
Ref: Globenewswire | Image: Jupiter Neurosciences
Related News:- Siolta Therapeutics Enters into a Joint Research Agreement with Cowellnex
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
